Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aspirin and Acute Myocardial Infarction

This article was originally published in The Tan Sheet

Executive Summary

Eighty-six percent of AMI patients judged to be appropriate recipients of aspirin therapy (n=90,000) were prescribed the drug during hospitalization, while 78% of those considered to be ideal recipients after hospital discharge (n=60,000) received prescriptions for aspirin, conclude Gerald O'Connor, PhD, Dartmouth Medical School, et. al., in a study on AMI quality of care published in the Feb. 17 Journal of the American Medical Association. The report comes from the Cooperative Cardiovascular Project, conducted as part of the Health Care Financing Administration's Health Care Quality Improvement Initiative. The researchers considered 186,800 patients participating in the Medicare fee-for-service program. Researchers also reviewed rates of appropriate treatment with Rx drug therapies, as well as advice to patients to quit smoking. O'Connor, et al, conclude "there is currently unrealized potential for more effective care of patients with AMI" and "some AMI patients experience unnecessary morbidity or mortality because they receive substandard medical care"

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS089442

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel